Susquehanna International Group
BTAI icon

Susquehanna International Group’s BioXcel Therapeutics BTAI Stock Holding History

Susquehanna International Group’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,158
Closed -$12.9K – 12531
2024
Q4 		$12.9K Buy
2,158
+20
+0.9% +$167 ﹤0.01% 11965
2024
Q3 		$20.9K Sell
2,138
-8,694
-80% -$117K ﹤0.01% 11619
2024
Q2 		$222K Buy
10,832
+5,195
+92% +$174K ﹤0.01% 10120
2024
Q1 		$254K Buy
+5,637
New +$269K ﹤0.01% 10085
2023
Q4 		– Sell
-1,216
Closed -$67.6K – 12387
2023
Q3 		$49.2K Sell
1,216
-14,471
-92% -$1.46M ﹤0.01% 11313
2023
Q2 		$1.67M Buy
15,687
+11,813
+305% +$3.93M ﹤0.01% 5526
2023
Q1 		$1.16M Buy
3,874
+2,610
+206% +$1.11M ﹤0.01% 6432
2022
Q4 		$435K Sell
1,264
-1,995
-61% -$482K ﹤0.01% 8231
2022
Q3 		$616K Sell
3,259
-1,722
-35% -$400K ﹤0.01% 7915
2022
Q2 		$1.05M Sell
4,981
-2,794
-36% -$588K ﹤0.01% 6404
2022
Q1 		$2.6M Sell
7,775
-3,339
-30% -$968K ﹤0.01% 4891
2021
Q4 		$3.62M Sell
11,114
-3,838
-26% -$1.65M ﹤0.01% 4324
2021
Q3 		$7.26M Buy
14,952
+1,540
+11% +$677K ﹤0.01% 3345
2021
Q2 		$6.24M Buy
13,412
+1,519
+13% +$828K ﹤0.01% 3626
2021
Q1 		$8.21M Buy
11,893
+2,360
+25% +$1.9M ﹤0.01% 3099
2020
Q4 		$7.05M Sell
9,533
-4,870
-34% -$3.79M ﹤0.01% 2929
2020
Q3 		$9.99M Buy
14,403
+14,160
+5,827% +$10.6M ﹤0.01% 2176
2020
Q2 		$206K Buy
+243
New +$158K ﹤0.01% 8988

Other funds holding BTAI

M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Susquehanna International Group's BTAI Position: Q1 2025 in Review

Susquehanna International Group sold out of BioXcel Therapeutics (BTAI) in Q1 2025, closing a stake of 2,158 shares — an estimated $12.9K sold.

Susquehanna International Group first reported a position in BTAI in Q2 2020 and held it in 18 quarters. The position peaked at $9.99M in Q3 2020. 31 funds tracked by Wall St. Rank hold BTAI as of Q1 2025.

  • Susquehanna International Group reported no remaining BioXcel Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Susquehanna International Group sold 2,158 BioXcel Therapeutics shares in Q1 2025, an estimated $12.9K.
  • Susquehanna International Group first reported a position in BioXcel Therapeutics in Q2 2020 and held it in 18 quarters.
  • Susquehanna International Group's BioXcel Therapeutics position peaked at $9.99M in Q3 2020.
  • 31 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2025.

Based on Susquehanna International Group's 13F filing for Q1 2025, filed 14 May 2025.